Clinical trial APHINITY
A randomised multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.
Cancers | |
---|---|
Organ | Breast |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Academic trial | Non |
Sponsor | Roche |
EudraCT Identifier | 2010-02290-241 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT01358877 |
Inclusion criteria | Non metastatic, operable HER2+ carcinoma of the breast |
Last update |